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Incidence of local recurrence and second 
primary tumors in resected stage I lung cancer 
From 1973 to 1985, 598 patients underwent resection for stage I non-small-cell lung cancer. There 
were 291 T1 lesions and 307 T2 lesions. The male/female ratio was 1.9:1. The histologic type was 
squamous carcinoma in 233 and nonsquamous carcinoma in 365. Lobectomy was performed in 511 
patients (85%), pneumonectomy in 25 (4%), and wedge resection or segmentectomy in 62 (11%). A 
mediastinal lymph node dissection was carried out in 560 patients (94%) and no lymph node 
dissection in 38 (6%). Fourteen postoperative deaths occurred (2.3%). Ninety-nine percent of the 
patients were observed for a minimum of 5 years or until death with an overall median follow-up of 
91 months. The overall 5- and 10-year survivals (Kaplan-Meier) were 75% and 67%, respectively. 
Survival in patients with T1 NO tumors was 82% at 5 years and 74% at 10 years compared with 68% 
at 5 years and 60% at 10 years for patients with T2 tumors (p < 0.0004). The overall incidence of 
recurrence was 27% (local or regional 7%, systemic 20%) and was not influenced by histologic type. 
Second primary cancers developed in 206 patients (34%). Of these, 70 (34%) were second primary 
lung cancers. Despite complete resection, 31 of 62 patients (50%) who had wedge resection or 
segmentectomy had recurrence. Five- and 10-year survivals after wedge resection or segmentectomy 
were 59% and 35%, respectively, significantly less than survivals of those undergoing lobectomy 
(5 years, 77%; 10 years, 70%). The 5- and 10-year survivals in the 38 patients who had no lymph node 
dissection were reduced to 59% and 32%, respectively. Apart from the favorable prognosis observed 
in this group of patients, three facts emerge as significant: (1) Systematic lymph node dissection is 
necessary to ensure that the disease is accurately staged; (2) lesser esections (wedge/segment) result 
in high recurrence rates and reduced survival regardless of histologic type; and (3) second primary 
lung cancers are prevalent in long-term survivors. (J THORAC CARDIOVASC SURG 1995;109:120-9) 
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Stage  I non-small-cell lung cancer epresents early 
cancer and is best treated by surgery whenever 
possible. Despite the expectation of long-term sur- 
vival after resection without adjuvant therapy, recur- 
rences or new cancers develop in a third of the 
patients, 1-3 emphasizing the need for continued 
surveillance. The frequency of reCurrences and new 
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primary cancers varies from one report to another. 
Because of the large number of patients with lung 
cancer treated by us at various stages of their 
disease, we have analyzed our experience with the 
surgical treatment of stage I tumors, focusing on 
tumor size, histologic type, extent of resection, and 
the incidence of recurrence and new cancers ob- 
served in the course of their follow-up. We here 
present our results. 
Patients and methods 
From 1973 to 1985 inclusive, 3145 patients with non- 
small-cell ung cancer were treated primarily at Memorial 
Hospital. Those treated elsewhere initially and then re- 
ferred to us with recurrence or metastases have been 
excluded. During that period, 598 patients underwent 
resection for pathologic stage I disease (T1 N0 M0 and T2 
NO MO). 
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Table I. Criteria for diagnosis of multiple lung 
cancers 
Metachronous tumors 
I. Histologic type different 
II. Histologic type the same, if: 
A. Free interval between cancers is at least 2years or 
B. Origin from carcinoma in situ or 
C. Second cancer in different lobe or lung, but: 
1. No carcinoma in lymphatics common t  both 
2. No extrapulmonary metastases at time of diagnosis 
Synchronous tumors 
I. Tumors physically distinct and separate 
II. Histologic type 
A. Different 
B. Same, but in different segment, lobe, r lung, if: 
1. Origin from carcinoma in situ 
2. No carcinoma in lymphatics common t  both 
3. No extrapulmonary metastases at time of diagnosis 
At thoracotomy the extent of intrathoracic disease was 
carefully assessed with particular eference to regional 
lymph nodes (N1 or N2). A complete resection of all 
disease in the lung was carried out, as well as a mediastinal 
lymph node dissection in the majority of patients. Postop- 
erative pathologic staging was done after the resected 
specimen was reviewed histologically and all regional 
nodes were assessed. Histologic type, tumor location, 
tumor size in centimeters, histologic learance at bron- 
chial and vascular esection margins, and visceral pleural 
involvement were r corded. The surgical and pathologic 
reports of all patients were carefully reviewed to ensure 
that the resection was complete, that no residual tumor, 
gross or microscopic, was left behind, and that no involved 
regional nodes (N1 and N2) were present. Tumor grading, 
vascular or lymphatic invasion within lung parenchyma, 
and flow cytometry were not routinely reported. However, 
several recent reports have suggested that these parame- 
ters adversely affect overall survival. 4-9 For that reason, 
200 specimens were randomly selected for blinded review 
by one of us (M.F.Z.). The tumors were categorized into 
well-differentiated, moderately differentiated, and poorly 
differentiated grades. 
We defined local recurrence as evidence of tumor within 
the same lung or at the bronchial stump, regional recur- 
rence as clinically or radiologically manifest disease in the 
mediastinum or in supraclavicular nodes, and distant 
recurrence as disease in the contralateral lung or outside 
the hemithorax. The criteria used for the diagnosis of 
multiple lung cancers are shown in Table I. 
Survival was calculated by the Kaplan-Meier method, 
including postoperative d aths and all lung cancer-related 
deaths. Differences in survival were determined by the 
log-rank test and differences in frequency data by the X z 
test. Significance was defined as p -- 0.05. 
The patients comprised 392 men and 206 women, a 
ratio of 1.9:1. The age range was 19 to 86 years with a 
median age of 62 years. The tumor was located in the right 
lung in 359 patients (60%) and in the left lung in 239 
(40%) (Table II). Thirteen of the tumors were in the main 
Table II. Location of the primary tumor 
Right lung Left lung 
Upper lobe 238 162 
Middle lobe 36 - -  
Lower lobe 77 69 
Main bronchus 5 8 
Intermediate bronchus 3 - -  
Total 359 239 
Table I l L  Extent of pulmonary resection 
No. of 
Resection patients 
Lobectomy 511 
Lobe only 445* 
Bilobes 60 
Lobe + sleeve 6 
Pneumonectomy 25 
Wedge resection 49* 
Segmentectomy 13" 
*No mediastinal lymph node dissection was carried out in9 lobectomies, 
26 wedge resections, and 3 segmentectomies. 
bronchus beyond 2 cm of the carina, 400 (67%) in the 
upper lobe, 146 in the lower lobe; and 36 in the right 
middle lobe. 
The histologic type was squamous carcinoma in 233 
patients (39%) and nonsquamous carcinoma in 365 (61%) 
(adenocarcinoma, 253; bronchoalveolar carcinoma, 98; 
large-cell carcinoma, 14). 
There were 291 T1 NO M0 tumors (49%) and 307 
(51%) T2 NO M0 tumors (51%). Sixty patients had tumors 
1 cm or smaller, of which 20 were radiographically occult 
tumor (TX lesions), 217 had tumors 2 cm or smaller, 351, 
3 cm or smaller, 164, larger than 3 cm to 5 cm, and 83, 
greater than 5 cm. The visceral pleura was involved in 113 
patients, 51 of whom had tumors 3 cm or smaller. 
Lobectomy was performed in 511 patients (85%), pneu- 
monectomy in 25 (4%), and wedge resection or segmen- 
tectomy in 62 (11%) (Table III). Of the latter group, 55 of 
62 patients (89%) had T1 tumors. A mediastinal lymph 
node dissection was carried out in 560 patients (94%) and 
lymph node sampling and no formal dissection i  38 (6%). 
Results 
Ninety-nine percent of the patients were observed 
for a min imum of 5 years or unti l  death (median 
follow-up: 91 months).  Only seven pat ients alive and 
well and one pat ient alive with disease were ob- 
served for less than 5 years f rom treatment.  Four-  
teen postoperat ive deaths occurred, an incidence of 
2.3%, all in pat ients with lobectomy. The causes of 
death included myocardia l  infarction in six, respira- 
tory fai lure or pneumonia  in six, renal  fai lure in one, 
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Fig. 1, Overall survival after resection of stage I non-small-cell lung cancer. 
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Fig. 2. Survival by T factor in resected stage I lung cancer. 
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and spontaneous esophageal perforation with sec- 
ondary mediastinitis n one. 
Twenty radiologically occult lung cancers were de- 
tected on sputum cytology, localized by bronchoscopy, 
and subsequently resected. Of these, 19 were squa- 
mous cell cancers and one was a bronchoalveolar 
carcinoma. The patient with bronchoalveolar carci- 
noma died of recurrence 2 years later. One patient 
with squamous cancer died of liver metastases 61/2 
years after initial treatment. The remainder are either 
alive and free of disease or have died of unrelated 
causes. The 5- and 10-year survivals of this small group 
of patients were 95% and 87%, respectively. 
The overall 5- and 10-year survivals were 75% and 
67% (Fig. 1). Survival of patients with T1 tumors 
was 82% at 5 years and 74% at 10 years, compared 
with 68% at 5 years and 60% at 10 years for those 
with T2 tumors (p < 0.0004) (Fig. 2). Because the 
exact diameter of each resected tumor was re- 
corded, each subset (T1 and T2) was analyzed 
further by tumor size in centimeters. We found that 
tumor size in centimeters influenced survival with 
significantp values between the ranges hown in Fig. 
3. Differences in survival were not significant be- 
tween (1) patients with tumors 2 cm or less in 
diameter and those with tumors 3 cm or less in 
diameter (p = 0.63), (2) patients with tumors 1 cm 
or less in diameter and those with tumors 2 cm or 
less in diameter (p -- 0.24), and (3) patients with 
tumors 1 to 2 cm in diameter versus 2 to 3 cm in 
diameter (p = 0.71). 
The extent of pulmonary resection influenced 
survival. Among 536 patients who had a lobectomy 
or pneumonectomy, the 5- and 10-year survivals 
were 77% and 70%, respectively, compared with 
59% and 35% in the 62 patients who had lesser 
resections (p = 0.026). 
The retrospective grading of the 200 randomly 
selected cases did not demonstrate any survival 
advantage by grade in these patients. 
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Fig. 4. Survival by visceral pleural invasion and tumor size. 
Visceral pleural involvement didnot affect overall 
survival (p = 0.06) but was a contributing adverse 
factor in patients with large tumors (Fig. 4). 
No difference in overall survival was identified in 
patients who had squamous cell tumors compared 
with those who had nonsquamous cancers (Fig. 5). 
However, among patients with nonsquamous can- 
cers, those with T1 lesions did better than those with 
T2 tumors (p = 0.0008) (Fig. 6). This survival 
difference was not apparent in patients with squa- 
mous cancers (p = 0.12). 
Survival was also calculated excluding wedge re- 
sections and segmentectomies and was 85% at 5 
years for patients with T1 tumors and 69% for those 
with T2 tumors, with an overall 5-year survival of 
77%. 
Recurrence. During the course of follow-up, re- 
currence developed in 159 of 598 patients (27%). Of 
these, 141 (89%) died of their disease, 7 are alive 
with disease (4%), and 11 (7%) have had successful 
control of their recurrence; 9 of the 11 are still alive 
and well and 2 have died of unrelated causes. 
In 60% of the patients with recurrent disease, the 
recurrence developed within the first 2 years after 
the operation. Although the incidence of recurrence 
diminished with time, 9% of patients had recurrence 
5 or more years after their nitial surgical treatment 
(Table IV). The longest free interval in our series 
was 12 years in a patient with a solitary brain lesion 
that was successfully removed. 
The overall incidence of recurrence was 27% and 
was not influenced by histotogic type. The first sites 
of recurrence, for all patients and according to 
histologic type, are shown in Table V. The first sites 
of recurrences in the overall group of patients were 
mostly distant (local 20%, regional 8%, and distant 
72%). The most common site of distant metastases 
was the brain, particularly in nonsquamous lung 
cancers. Local or regional recurrence was slightly 
more common in patients with squamous carcinoma 
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Table IV, Frequency of recurrences from initial 
treatment by year of follow-up 
Years after 
resection No. % 
1 55 35 
2 39 25 
3 27 17 
4 16 10 
5 7 4 
>5 15 9 
Total 159 100 
as compared with those with nonsquamous lung 
cancers (32% versus 26%). 
Lesser resections than lobectomy and no lymph 
node dissection had adverse effects on recurrence 
and survival. Despite a complete resection, 31 of 62 
patients (50%) who had wedge resection or segmen- 
tectomy had recurrence (p = 0.00002), 14 of whom 
had local or regional recurrences. Twenty-one of 38 
(55%) patients who had no lymph node dissection 
had recurrence (p = 0.00008), 18 of whom had local 
or regional recurrences (71%). Only 5% of all 
recurrences were local or regional recurrence in 
patients who had mediastinal lymph node dissec- 
tion. The 5- and 10-year survivals after wedge resec- 
tion or segmentectomy were 59% and 35% (p = 
0.026); the 5- and 10-year survivals in those who had 
no lymph node dissection were 59% and 32% Co < 
0.0005). 
The incidence of recurrence was influenced by the 
T factor and by tumor size in centimeters. The 
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Table V. Sites of first recurrence in 159 patients 
Sites of recurrence 
All patients Squamous Ca Nonsquamous Ca 
First site (anytime) First site (anytime) First site (anytime) 
Local 
Stump 5 
Lung 27* 
Regional (N2-N3) 
Distant 
Brain 51 (54) 
Lung 20 (29) 
Liver 14 (18) 
Bone 11 (24) 
Other 8 
Disseminated 5 
Local + distant 
Regional + distant 
Total 
32 12 20 
1 4 
11 16 
13 6 7 
109 38 71 
13 (13) 38 (41) 
7 (9) 13 (20) 
11 (12) 3 (6) 
3 (5) 8 (19) 
3 5 
1 4 
3 1 2 
2 - -  2 
159 57 102 
*Twenty-one of 27 treated by wedge resection or segmentectomy. 
difference was statistically significant between T1 
and T2 tumors (p = 0.0004), between tumors 3 cm 
or smaller and those greater than 3 cm but equal to 
or less than 5 cm (p = 0.03), and between tumors 
larger than 3 cm to 5 cm and those greater than 5 cm 
0) = 0.03). 
Multiple primary cancers. A total of 206 patients 
had second cancers, an overall incidence of 34%. 
This incidence was similar between histologic types 
(squamous carcinoma 32%, nonsquamous cancer 
36%). The second primary tumors were synchro- 
nous in 24 and metachronous in 182 patients (Table 
VI). One third of the multiple cancers were lung 
cancers. A total of 69 patients had two primary lung 
cancers, 14 of which were synchronous and 55 
metachronous (10 before, 45 after). Fifteen patients 
had a third cancer, five of whom had triple lung 
cancers, four from the metachronous group and one 
from the synchronous group. 
Late recurrences and new cancers. In our series, 
391 patients with resected stage I non-small-cell 
lung cancer lived 5 or more years (204 T1 NO and 
187 T2 NO). Fifteen recurrences occurred after 5 
years. Two of these were local recurrences: One 
patient who had a wedge resection was treated by 
completion lobectomy and remains alive and dis- 
ease-free 10 years later. Another had a local recur- 
rence 7 years after a lobectomy and sleeve resection 
and was treated by radiation. He also remains alive 
and well at 81/2 years. Of the remainder, eleven died 
of their disease, one is alive and well after resection 
of a brain metastasis, and one is alive and well after 
resection of a rib metastasis. In addition, new can- 
cers developed 5 or more years after treatment of 
Table VI. Incidence of multiple cancers in 598 
patients* 
Site Before Simultaneous After Total 
Lung 10 14 45 69 (33%) 
Breast 25 3 6 34 
Head and neck 21 1 4 26 
Colon/rectum 8 - -  8 16 
Bladder 8 1 5 14 
Cervix/uterus 6 3 1 10 
Prostate 3 - -  3 6 
Ovary 1 - -  - -  1 
Esophagus - -  - -  3 3 
Stomach - -  - -  3 3 
Pancreas - -  - -  6 6 
Kidney - -  - -  3 3 
Melanoma 6 1 - -  7 
Hodgkin's i - -  - -  i 
Lymphoma - -  1 - -  i 
Myeloma - -  - -  3 3 
Leukemia 1 - -  - -  1 
Thymoma 1 - -  - -  1 
Sarcoma 1 - -  - -  1 
Total  92 24 90 206 
*A third cancer developed in patients from this group--eight cancers of 
the lung, two of the larynx, and one each of the colon, prostate, skin 
(melanoma), and bone (multiple myeloma). 
the initial lung cancer in 35 patients. Twenty of them 
were new lung cancers (Table VII). 
To date, 279 patients are alive and well 5 to 19 
years after treatment with a median follow-up of 119 
months. Seven additional patients were lost to fol- 
low-up 18 to 55 months after treatment (median 
follow-up, 36 months). Sixteen are alive with disease 
at 31/2 to 16 years after treatment (median follow-up, 
91 months). There were 289 late deaths, 113 of 
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Table VII. Incidence of recurrence and new cancers 
in patients alive and well after 5 or more years 
All stage 
T1 NO T2 NO I 
Al ive and well 204 187 391 
Recur rence  8 7 15 
Loca l  2 1 3 
Stump 1 - -  1 
Lung 1 1 2 
Reg iona l  (N2) - -  1 1 
Distant  6 5 11 
Bra in  2 3 5 
Lung 1 1 2 
Liver - -  1 1 
Bone + lung 1 - -  1 
Bra in  + bone 1 - -  1 
Bone 1 - -  1 
New cancers  20 15 35 
Lung 13 7 20 
B ladder  1 2 3 
Co lon / rectum 1 2 3 
Breast  2 - -  2 
Tongue - -  1 1 
Pharynx  - -  1 1 
S tomach 1 - -  1 
Pancreas  1 - -  1 
Uterus  - -  1 1 
K idney  1 - -  1 
Prostate  - -  1 1 
unrelated causes and 176 either of the original or 
subsequent lung cancer. Deaths from unrelated 
causes were due to a new cancer other than lung in 
25, cardiorespiratory problems in 51 (myocardial 
infarction, chronic obstructive pulmonary disease, 
pneumonia, pulmonary embolism, or stroke), he- 
patic failure caused by cirrhosis in 4, suicide in 3, 
and natural causes while free of cancer in 30. 
Discussion 
Few lung cancers are potentially curable. For 
those patients with stage I non-small-cell carcinoma, 
however, surgical resection offers a significant 
chance of cure. 1°-16 Radiographically occult carcino- 
mas of the lung detected on sputum cytologic exam- 
ination represent a very small group of lung cancers, 
but early removal of these tumors after localization 
results in cancer cure in the vast majority. 
In 1977, we 17 reported our preliminary survival 
results with the surgical treatment of stage I lung 
cancer and demonstrated favorable results with 
complete resection combined with mediastinal 
lymph node dissection. By 1983, follow-up data were 
available for at least 5 years on 136 patients treated 
by lobectomy or pneumonectomy. 12 The 5-year sur- 
vival was 83% for patients with T1 tumors and 65% 
for those with T2 tumors, with an overall 5-year 
survival of 72%. No local recurrence was observed 
in this group of patients and only three had regional 
lymph node metastases, emphasizing the need for a 
complete lymph node dissection to ensure the ab- 
sence of nodal metastasis and also emphasizing the 
need to do a lobectomy in patients with stage I lung 
cancer egardless of the small size of the tumor or its 
peripheral position. 
In our early experience, we had not found vascu- 
lar or lymphatic invasion or grading to have prog- 
nostic significance. As a result, these parameters 
were not routinely recorded in our pathology re- 
ports. Although our current reporting is more stan- 
dardized and these observations are now noted, we 
attempted to address grading by reviewing 200 
randomly selected cases from our series and found 
that grading had no predictive value on survival in 
these patients who had complete resections. 
Vascular or lymphatic invasion as a predictor of 
survival has been controversial. The Veterans Ad- 
ministration Surgical Oncology Study Group had 
reviewed 865 resections for lung cancer, and the 
presence or absence of lymphatic or blood vessel 
invasion was recorded in 90% of the cases, s Blood 
vessel invasion was found to have no predictive 
value, but lymphatic invasion did in patients with 
squamous cell cancers. In a more recent publication, 
blood vessel invasion was reported to be a main 
predictor of recurrence in T1 NO M0 disease non- 
small-cell ung cancer. 4 Of 95 patients treated by 
resection, 16 had blood vessel invasion and all have 
died of their cancer. However, the distinction be- 
tween blood vessel and lymphatics is not always 
possible even with the use of special stains. 
The value of flow cytometry to assess the deoxyri- 
bonucleic acid content has also been controversial, is 
Although reports have noted that deoxyribonucleic 
acid assessment is valuable, 5'9 this was not prognos- 
tic in our experience 19or in that of the Lung Cancer 
Study Group. 3 
A similar controversy exists between advocates of 
elective segmentectomy or wedge resection 2° and 
those who recommend a lobectomy as the proce- 
dure of choice. In one series, patients with wedge 
resection did better than those treated by lobectomy 
or pneumonectomy because median tumor size was 
smaller. 4In another series, patients with tumors less 
than 2 cm in diameter within the T1 N0 group had a 
survival advantage. 21 It was concluded that deep- 
seated lesions necessitate a lobectomy, but lesser 
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resections are justified in patients with peripheral 
tumors less than 2 cm in diameter, because they do 
better and perhaps hould be analyzed separately. 
These two reports contradict the observations made 
by the Lung Cancer Study Group 22 and by our 
current series. Our experience confirms that any 
resection less extensive than lobectomy places the 
patient at an increased risk of local recurrence and 
decreases the chances of long-term survival. Only in 
those patients with compromised cardiopulmonary 
function do we recommend a conservative r section 
such as segmentectomy or wedge resection. 
Regardless of the extent of pulmonary resection, 
systematic mediastinal lymph node dissection should 
be routinely performed to stage the disease accurately 
by ascertaining that lymphatic metastases are bsent. 
Recurrence after initial treatment was identified 
by radiographic or laboratory evidence and when- 
ever possible by pathologic onfirmation. Local and 
regional recurrences are the result of inadequate ini- 
tial excision and are considered torepresent persistent 
disease, not a second carcinoma. Recurrences at any 
site are most commonly detected within the first 2 
years after treatment and diminish in occurrence with 
time. However, inasmuch as these patients live long 
and overcome their first carcinoma, they remain atrisk 
for second carcinomas. When a complete, potentially 
curative resection of a primary carcinoma of the lung is 
performed, when the margins are clear, and when 
lymph node metastasis is absent, a y new lesion, even 
if in the same lung, may well represent a new and 
separate primary tumor. Guidelines for acceptance of
a carcinoma s a new and separate lung carcinoma 
were reported by us 23 and are shown in Table I. The 
diagnosis i  most convincing when the new lesion is in 
the contralateral lung and the histologic type of the 
new tumor is different. 
The Lung Cancer Study Group had stated that 
cancer recurrence represents treatment failure 
whereas development of new cancers uggests per- 
sistent exposure to etiologic risk factors. 24 We con- 
cur with this explanation and agree with the need for 
continued surveillance beyond 5 years. The fre- 
quency with which second primary tumors are de- 
tected in this group of patients is high and poses a 
threat to survival despite the potentially curative 
resection of the initial primary lung cancer. 
The emphasis on 5-year survival may be mislead- 
ing in patients with treated cancers with low recur- 
rence rates. In resected stage I non-small-cell lung 
cancer, a significant proportion of patients die of 
other causes and free of cancer. In our series, the 
incidence of deaths from unrelated causes was 19%. 
In many studies, patients with prior head and neck, 
lung, and breast cancers have been excluded, as well 
as patients with prior cancers treated within 5 
years. 24"25 In our series, inclusion of previously 
treated cancers including head and neck cancers did 
not adversely affect survival. 
The high frequency of the development of second 
primary lung cancers was also noted in our early 
report on 136 patients treated by resection for stage 
I lung cancer (32% second cancers, 34% of which 
were second primary lung cancers). Our current 
review notes the same high frequency, namely, a 
34% incidence of second cancers, a third of which 
are second lung cancers. 
Because vitamin A and retinoids were found to be 
strong inhibitors of epithelial cancer progression i
experimental carcinogenesis, everal randomized 
studies are currently in progress to assess the merits 
of retinoids in improving the disease-free interval by 
preventing secondary aerodigestive cancers or re- 
currence in patients cured of an early lung can- 
cer.26, 27 The data re still viewed as preliminary and 
will require several years of follow-up before defin- 
itive conclusions can be drawn. At this time, it is 
recommended that retinoids and vitamin A be of- 
fered only in protocol settings. 
Summary and conclusions 
1. Pathologic stage I lung cancer is early cancer 
and is best treated surgically. 
2. Lobectomy is the procedure of choice even if 
the tumor is small and peripheral. Wedge resection 
or segmentectomy should be limited to patients with 
prior pulmonary resections, poor pulmonary re- 
serve, or other major medical problems that pre- 
clude a safe lobectomy. 
3. The mediastinal evaluation must be thorough 
to ensure that the patient has early stage I disease. 
Computed tomographic scans help in identifying 
enlarged mediastinal lymph nodes. Whether one 
chooses to do a mediastinoscopy or proceed irectly 
to a thoracotomy, a systematic nodal evaluation, 
preferably by dissection of all accessible nodes, will 
ensure that no nodal disease is present and the 
favorable prognostication will be more accurate. 
4. Histologic type and visceral pleural invasion 
per se are not prognostic, but the extent of the 
disease and its resectability are prognostic and affect 
survival. 
5. Tumor size is important. The smaller the pri- 
mary tumor, the better the prognosis. Tumors de- 
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tected when less than 1 cm in diameter do best, and 
tumors greater than 5 cm do poorest. 
6. Recurrences do occur, despite early-stage dis- 
ease, mostly in the first 2 years, but nearly 10% 
develop 5 or more years after treatment. 
7. Because these patients live long and overcome 
their first cancer, they are at risk for second cancers. 
Therefore, an indefinite period of surveillance well 
beyond 5 years is necessary. 
We gratefully acknowledge Phyllis Byczek for her assis- 
tance in collating the data and her tireless efforts in 
obtaining status follow-up on all patients. 
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Discussion 
Dr. L. Penfield Faber (Chicago, Ill.). Dr. Martini and 
the group from Memorial have established another "gold 
standard" for the surgical treatment of non-small-cell lung 
cancer. The earlier report by Drs. Martini and Beattie 
recommended lobectomy as the resection of choice for 
stage I lung cancer. The projected survival at 5 years for 
patients with T1 NO disease after lobectomy was approx- 
imately 80%. To me, a gold standard procedure is one to 
which other variations of resection are compared. Those 
of us who are reporting results of segmental resections, 
wedge resections, or resections by video-assisted thoracic 
surgical techniques must document similar results if these 
procedures are to become accepted as standard. This 
exquisitely defined study with exquisitely defined lymph 
node resection and surgical/pathologic staging sets the 
standard. It also provides patients with stage I disease a 
degree of optimism. 
I agree that it is important o accomplish a complete 
lymphadenectomy to assure that these are stage I lesions. 
I concur with Dr. Martini that lymphadenectomy is im- 
portant for staging and also achieves a more complete 
resection with an enhanced cure rate. 
Dr. Martini, how do you define and differentiate local 
recurrence from a second primary. A review of the 
literature of lung cancer shows that second primaries have 
various definitions, such as the second tumor appearing 
more than 2 years after the initial resection or the tumor 
arising in another lobe, having a contralateral location, 
and being of a different histologic type. Definitions for a 
second primary do vary, and it can be troublesome to 
differentiate the development of a second primary from 
locoregional recurrence. 
My second question concerns the recommended ap- 
proach to solitary metastatic disease in organs other than 
the brain. What should be done about resection of solitary 
metastatic tumors in other organs that would include the 
adrenal gland, the contralateral lung, and the liver? 
Dr. Martini. We define local recurrence as disease 
found in lung in patients who had a lesser esection than 
a lobectomy or disease found at the bronchial resection 
margin after a lobectomy or pneumonectomy. We define 
regional recurrence as development of N2 or N3 disease 
despite acareful mediastinal lymph node evaluation at the 
initial operation. All other sites of recurrence are referred 
to as distant recurrence. 
The diagnosis of a new primary tumor is most convinc- 
ing when the histologic type of the new tumor is different. 
Also accepted as a new primary is a new lesion in the 
contralateral lung or different lobe with no carcinoma in 
lymphatics common to both. We have also accepted as 
multiple lung primaries, squamous carcinomas in the 
same lobe when we have clearly identified the origin of 
each from a carcinoma in situ. 
The best treatment for a solitary distant metastasis after 
adequate control of a primary tumor presumed to be stage 
I is still an unresolved question. In our opinion, if the 
solitary area of metastasis is resectable, it should be 
resected, just as we have done with solitary brain metas- 
tasis. We do not have the same experience with the 
adrenal gland. We have on occasion resected solitary skin 
metastases or rib metastases with a resultant prolonged 
survival. 
It is important o remember that the treatment for a 
patient with a solitary lung lesion, be it metastatic or a new 
primary, ought to be surgical with expectations of pro- 
longed survival. 
Dr. John R. Benfield (Sacramento, Calif.). An important 
part of your presentation has been that patients who have 
had lesser resections and lesser lymph node dissections 
have fared less well than those who have had the more 
extensive procedures. 
Because this was a retrospective study, I am curious to 
know what selection criteria were used for the patients who 
had these lesser resections. Is it possible that the lesser 
survivals among those patients were, at least in part, the 
result of factors other than the operations that were done? 
Dr. Martini. We were heavily influenced from the outset 
by the fact that the surgical treatment of patients with lung 
cancer, however small or early, should be no less than a 
lobectomy. We offered lesser esections only to patients with 
limited cardiopulmonary reserve caused by chronic obstruc- 
tive pulmonary disease or prior pulmonary resection for lung 
cancer and, at times, after a mistaken frozen section diagno- 
sis of metastasis or benign disease. When we did that, we 
noted a local recurrence rate of 19%. The largest series in 
this country comes from Rush-Presbyterian-St. Luke's Med- 
ical Center eported by Jensik, Faber, Kittle and Warren. In 
this series elective segmentectomies have resulted in a 12% 
to 15% incidence of local recurrence. 
Because of this fact, we believe very strongly that in a 
patient with adequate lung reserve who has early lung 
cancer, there is no justification to do a miniresection and 
risk local recurrence. 
Dr. Donald L. Morton (Santa Monica, Calif.). What 
pathologic riteria did you use to determine the absence 
of lymph node metastases? We recently reviewed a series 
of patients with lung cancer whose mediastinal nodes had 
no evidence of metastases by standard histopathologic 
examination with hematoxylin and eosin stains. However, 
more sensitive immunohistochemical stains revealed mi- 
crometastases in 30% of the dissection specimens. I am 
therefore intrigued by your 30% rate of recurrence in 
patients without nodal metastases. I put forth the hypoth- 
esis that most patients with recurrence have regional node 
micrometastases that are too small to be detected by 
routine hematoxylin and eosin staining. 
Dr. Nael Martini. Dr. Morton, this is a very interesting 
piece of information. Our only method of determining 
that a patient has no regional lymph node metastasis has 
been the meticulous histologic light microscopic review of 
any lymph nodes we submitted. Because we were doing 
lymph node dissections, the approximate number of 
lymph nodes submitted from the mediastinum varied from 
25 to 40. Admittedly, many intraparenchymal and seg- 
mental nodes may be overlooked if step sectioning is not 
done. 
